A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost biosimilar version of it is slated to hit the market this year.

The Centers for Medicare & Medicaid Services just announced the next 15 brand-name medicines selected for Medicare’s drug price negotiation program, which mandates price reductions of at least 25%.

The Association for Accessible Medicines and its Biosimilars Council have released an analysis undertaken by the IQVIA Institute for Human Data Science on behalf of AAM assessing the impact of patent ...

CVS Health Inc. CVS on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to ...

February 13, 2026) - VRC Medical Services, a women-owned specialty pharmaceutical distribution company supporting clinical research, announced the launch of a dedicated comparator support program ...

The Association for Accessible Medicines’ annual U.S. Generic & Biosimilar Medicines Savings Report, in partnership with the IQVIA Institute, reveals that the use of Food and Drug Administration ...

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo (Reuters) -The U.S. Food and ...

Samsung Bioepis Co., the biosimilar drug development arm of Samsung Group, said Thursday it plans to launch its ophthalmology ...

The FDA has decided that biosimilar medications must have unique naming features, distinguishing them from brand-name biologics in a move to improve patient safety, according to a STAT news report. 1.

Biosimilar natalizumab (Tyruko) is approved by EMA, US FDA, MHRA etc. and article is intended only for the HCP audience in ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...